Australia Neurovascular Devices Market (2025-2030)
The Australia Neurovascular Devices Market was valued at $60.67 Million in 2025 and projected to reach to $89.09 Million by 2030, representing a compound annual growth rate of 8.0%. Australia's neurovascular devices market is positioned for steady growth through 2030, driven by an aging population and increasing incidence of stroke and neurological conditions.
Australia Neurovascular Devices Market Trends and Insights
- This 8.0% compound annual growth rate reflects Australia's advancing healthcare infrastructure and increasing prevalence of cerebrovascular and neurological disorders.
- Australia's aging population and rising demand for minimally invasive interventional procedures are driving adoption of neurovascular technologies across major metropolitan hospitals and specialized neurovascular centers. The Australian market benefits from strong regulatory frameworks, high healthcare spending, and early adoption of innovative medical devices.
- Australia's neurovascular device sector is supported by skilled interventional neuroradiologists and neurosurgeons, alongside growing patient awareness of stroke prevention and treatment options.
- Between 2025 and 2030, Australia is expected to see increased investment in neurovascular infrastructure and expanded reimbursement pathways for advanced devices, positioning the country as a key growth market within the Asia Pacific region..
Key Market Statistics
- CAGR (2025-2030) 8.0% CAGR
- Market Size, 2025 ~USD 60.67 Million
- Forecast, 2030 ~USD 89.09 Million
- Country Australia
Australia Neurovascular Devices Market Overview
Market Valuation :
Australia's neurovascular devices market is valued at USD 60.67 million in 2025, with projections to reach USD 89.09 million by 2030, representing a robust 8.0% CAGR.
Aging Population Driver :
Australia's rapidly aging demographic is significantly increasing the prevalence of cerebrovascular and neurological disorders, driving demand for advanced neurovascular interventions and devices.
Minimally Invasive Adoption :
Growing preference for minimally invasive procedures across Australian healthcare facilities is accelerating adoption of neurovascular devices, improving patient outcomes and reducing recovery times.
Healthcare Infrastructure Growth :
Australia's advancing healthcare infrastructure, including state-of-the-art medical facilities and skilled interventional radiologists, supports market expansion and device innovation adoption.
Australia Neurovascular Devices Market Dynamics
- The country's well-developed healthcare system and strong adoption of minimally invasive technologies create favorable conditions for market expansion.
- Investment in medical infrastructure and training of interventional specialists further support this trajectory. The Australian market benefits from favorable reimbursement policies and regulatory frameworks that encourage innovation.
- Rising healthcare expenditure and patient awareness of advanced treatment options are expected to sustain the 8.0% CAGR.
- Key opportunities exist in expanding access to neurovascular procedures in regional areas and developing cost-effective device solutions tailored to the Australian market..
Related Ecosystem
Key Takeaways
- Australia's neurovascular devices market is valued at USD 60.67 million in 2025 and is forecast to grow to USD 89.09 million by 2030, representing an 8.0% CAGR.
- Australia's aging demographic and rising stroke incidence are primary drivers of neurovascular device adoption across the country.
- Australia's robust healthcare system and favorable reimbursement environment support sustained market growth through 2030.
- Australia's skilled interventional workforce and early technology adoption position it as a leading neurovascular market in Asia Pacific.
Neurovascular Devices Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CLOT RETRIEVER DEVICES (Type 2023–2030) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.3% from 2025 to 2030 |
| Largest Segment | HOSPITALS AND AMBULATORY SURGICAL CENTERS (End User) |
| Market Size Base Year (Billions) | ~USD 4.7 (2025) |
| Revenue Forecast (Billions) | ~USD 7.33 (2030) |
| Segments Covered | Disease Pathology, Type, Type 2023–2030, End User |
Australia Neurovascular Devices Market Report Segmentation
4 segment dimensions are covered across the global market.
By Disease Pathology
- Arteriovenous Malformations & Fistulas
- Arteriovenous Malformations And Fistulas
- Carotid Artery Stenosis
- Cerebral Aneurysms
- Device For Cerebral Aneurysms
- Ischemic Strokes
- Other Disease Pathologies
By Type
- Balloon Catheters
- Bare Detachable Coils
- Carotid Artery Stents
- Clot Retriever Devices
- Coated Detachable Coils
- Embolic Coils
- Embolic Protection Devices
- Flow Diversion Devices
- Intracranial Stents
- Liquid Embolic Agents
- Microcatheter
- Microcatheters
- Occlusion Balloon Catheters
- Other Devices
- Suction & Aspiration Devices
- Vascular Snares
By Type 2023–2030
- Balloon Catheters
- Clot Retriever Devices
- Other Devices
- Suction & Aspiration Devices
- Vascular Snares
By End User
- Hospitals And Ambulatory Surgical Centers
- Research And Academic Institutes
- Specialty Clinics
Target Audience
- Medical Device Manufacturers : Manufacturers need Australia-specific market data to develop localized product strategies, understand competitive dynamics, and identify distribution partnerships in this growing healthcare market.
- Healthcare Investors & PE Firms : Investment professionals require detailed Australian market forecasts and growth drivers to evaluate acquisition targets, fund allocation decisions, and portfolio company expansion opportunities.
- Hospital & Healthcare Administrators : Hospital leaders need market insights to justify capital expenditure on neurovascular equipment, plan departmental budgets, and align procurement strategies with market trends.
- Market Entry & Strategy Consultants : Consultants advising companies on Australian market expansion require granular data on market size, growth rates, and regional dynamics to develop credible go-to-market strategies.
- Regulatory & Compliance Officers : Regulatory professionals need Australia-specific market context to understand the competitive landscape, anticipate regulatory changes, and ensure compliant product positioning in this market.
Key Companies in the Australia Neurovascular Devices Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Turnkey automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital solutions, |
| NOLATO | Sweden | Public Company | Medical components and systems (Medical Solutions),Pharmaceutical primary packaging and labware,EMC shielding and thermal management (Compatherm, Compashield, Trishield), |
| CONMED CORPORATION | United States | Public Company | Sports medicine & orthopedic arthroscopy (BioBrace, TruShot, Y-Knot, Agro, powered resection, fluid management, visualization),Hall large and small bone power tools,General surgery: AirSeal insufflation, Buffalo smoke evacuation, endomechanical (trocars, retrieval bags, suction-irrigation, graspers, scissors, dissectors), |
| LIVANOVA PLC | United Kingdom | Public Company | Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion, perfusion disposables and services),Neuromodulation (VNS Therapy for epilepsy and depression, OSA development programs), |
| BIOGEN | United States | Public Company | Multiple sclerosis therapies (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SMA and rare neuromuscular (SPINRAZA, QALSODY),Alzheimer’s and neuropsychiatry (LEQEMBI, ZURZUVAE), |
| JOHNSON & JOHNSON | United States | Public Company | Oncology,Immunology,Neuroscience & Other Innovative Medicine, |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
| PENUMBRA, INC. | United States | Public Company | Neurovascular mechanical thrombectomy (Penumbra System, RED, JET, ACE, ENGINE, 3D Revascularization),Peripheral thrombectomy (Indigo, Lightning Flash, Lightning Bolt 7, CAT RX),Neuro embolization coils and POD/PAC platforms, |
| MICROPORT SCIENTIFIC CORPORATION | China | Public Company | Cardiovascular Devices (coronary stents, balloons, accessories),Orthopedics Devices (reconstructive joints, spine, trauma),Cardiac Rhythm Management (pacemakers, CRT, defibrillators), |
| KANEKA CORPORATION | Japan | Public Company | PVC and Vinyl Polymers (PVC, crosslinked PVC, PVC-PVAc, paste PVC, chlorinated PVC),Specialty Additives and Engineering Resins (impact modifiers, processing aids, tougheners, engineering resin for injection molding),High-Performance Films and Thermal Materials (polyimide film, optical films, graphite sheets, multi-layer insulation), |
| ASAHI INTECC CO., LTD | Japan | Public Company | PCI guide wires and cardiology catheters,Peripheral and cerebrovascular guide wires and microcatheters,Angiography and general-purpose catheters, |
| JAPAN LIFELINE CO., LTD | Japan | Public Company | Electrophysiology and Ablation Products,Cardiac Rhythm Management and Defibrillation,Cardiovascular and Endografting, |
ATS AUTOMATION TOOLING SYSTEMS INC
ATS Automation Tooling Systems Inc is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for manufacturing industries.
NOLATO
Nolato is a Swedish public company founded in 1938 with 5,607 employees. The company operates in the manufacturing and materials processing sectors.
CONMED CORPORATION
CONMED Corporation is a United States-based public company founded in 1970 with 3,900 employees. The company operates in the medical device and healthcare equipment industry.
LIVANOVA PLC
LivaNova PLC is a United Kingdom-based public company founded in 2015 with 3,300 employees. The company specializes in medical devices and healthcare solutions.
BIOGEN
Biogen is a United States-based public company founded in 1978 with 7,500 employees. The company specializes in biotechnology and biopharmaceutical development.
JOHNSON & JOHNSON
Johnson & Johnson is a United States-based public company founded in 1886 with 138,200 employees. The company is a diversified healthcare conglomerate operating in pharmaceuticals, medical devices, and consumer health.
TERUMO CORPORATION
Terumo Corporation is a Japanese public company founded in 1921 with 30,591 employees. The company specializes in medical devices and healthcare products.
PENUMBRA, INC.
Penumbra, Inc. is a United States-based public company founded in 2004 with 4,700 employees. The company develops and manufactures medical devices for vascular and neurovascular interventions.
MICROPORT SCIENTIFIC CORPORATION
MicroPort Scientific Corporation is a Chinese public company founded in 1998 with 6,547 employees. The company specializes in medical device manufacturing and cardiovascular solutions.
KANEKA CORPORATION
Kaneka Corporation is a Japanese public company founded in 1949 with 11,762 employees. The company operates in chemicals, plastics, and medical device manufacturing.
ASAHI INTECC CO., LTD
Asahi Intecc Co., Ltd is a Japanese public company founded in 1976 with 9,473 employees. The company specializes in medical devices and interventional equipment.
JAPAN LIFELINE CO., LTD
Japan Lifeline Co., Ltd is a Japanese public company founded in 1981 with 1,304 employees. The company operates in the medical device and healthcare industry.
Reasons to Buy this Report
- Market-Specific Sizing : Obtain precise valuation data for Australia's neurovascular devices market with verified 2025 baseline (USD 60.67M) and 2030 forecasts, enabling accurate budget allocation and revenue projections.
- Demographic Insights : Understand Australia's aging population dynamics and their direct correlation to neurovascular disease prevalence, allowing targeted product development and market entry strategies.
- Regulatory & Reimbursement Landscape : Gain insights into Australia-specific regulatory pathways, TGA approval processes, and Medicare reimbursement structures critical for successful market penetration and commercialization.
- Competitive Positioning : Identify key competitors, market gaps, and opportunities specific to Australia's healthcare system, enabling differentiated positioning and strategic partnerships with local stakeholders.
- Growth Opportunity Assessment : Leverage the 8.0% CAGR forecast to identify high-growth segments, regional expansion opportunities, and emerging applications within Australia's neurovascular market through 2030.
Frequently asked questions
What is the current size of Australia's neurovascular devices market?
Australia's neurovascular devices market is valued at USD 60.67 million in 2025 and is expected to grow at an 8.0% CAGR through 2030.
What is the projected market size for Australia's neurovascular devices by 2030?
Australia's neurovascular devices market is projected to reach USD 89.09 million by 2030, up from USD 60.67 million in 2025.
What factors are driving growth in Australia's neurovascular devices market?
Australia's market growth is driven by an aging population, rising stroke prevalence, advanced healthcare infrastructure, skilled interventional specialists, and favorable reimbursement policies.
How does Australia's neurovascular market compare to other Asia Pacific countries?
Australia represents a mature and well-developed neurovascular market within Asia Pacific, characterized by high healthcare spending, strong regulatory standards, and early adoption of innovative technologies.
What is the CAGR for Australia's neurovascular devices market from 2025 to 2030?
Australia's neurovascular devices market is expected to grow at a compound annual growth rate (CAGR) of 8.0% between 2025 and 2030.
RESEARCH METHODOLOGY
The study included four main activities to estimate the current size of the neurovascular devices market. First, extensive secondary research was performed to collect information on the market, including related and parent markets. The next step was to validate these findings, assumptions, and market size estimates through primary research with industry experts across the value chain. We used both top-down and bottom-up approaches to develop a comprehensive estimate of the overall market size. Finally, we applied market segmentation and data triangulation techniques to assess the sizes of segments and subsegments within the market.
Secondary Research
The secondary research process involved extensively using various sources, including directories, databases like Bloomberg Business, Factiva, and D&B Hoovers, as well as white papers, annual reports, company house documents, investor presentations, and SEC filings. This research aimed to gather information valuable for a thorough, technical, market-focused, and commercial study of the neurovascular devices market. It also helped obtain key insights about industry leaders, market classification, and segmentation based on current industry trends, down to the smallest details. Additionally, a database of leading industry players was compiled through this secondary research.
Primary Research
In the primary research process, we conducted interviews with various sources from both the supply and demand sides to collect qualitative and quantitative information for this report. On the supply side, we spoke with industry experts, including CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from prominent companies and organizations involved in the neurovascular devices market. For the demand side, we engaged with industry experts, purchasing and sales managers, doctors, and personnel from research organizations. This primary research was crucial to validate market segmentation, identify key players in the industry, and gather insights on important industry trends and market dynamics.
A breakdown of the primary respondents for the neurovascular devices market is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Others include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The research methodology used to estimate the size of the neurovascular devices market includes the following details.
The market sizing was undertaken from the global side.
Country-level Analysis: The size of the neurovascular devices market was determined from annual presentations by leading players and secondary data available in the public domain. The share of products and services within the overall neurovascular devices market was derived from secondary data and validated by primary participants to estimate the total market. Primary participants further confirmed the validity of these data numbers.
Geographic Market Assessment (By Region & Country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each stage, the assumptions and approaches were verified through industry experts contacted during primary research. Given the limitations of data available from secondary research, revenue estimates for individual companies—covering the overall neurovascular devices market and regional market assessments—were determined based on a detailed analysis of their product offerings, geographic reach or strength (whether direct or through distributors or suppliers), and the market shares of leading players in specific regions and countries.
Global Neurovascular Devices Market Size: Bottom-Up and Top-Down Approach
Data Triangulation
After determining the overall size from the market size estimation process described above, the total market was divided into multiple segments and subsegments. The data triangulation and market breakdown procedures explained below were applied, where applicable, to complete the overall market analysis and derive precise statistics for various market segments and subsegments. The data was triangulated by examining diverse factors and trends from both the demand and supply sides. Additionally, the market size was validated using both top-down and bottom-up methods.
Market Definition
The neurovascular devices market includes medical technologies and tools designed for monitoring, managing, and treating neurovascular diseases. It encompasses devices used to treat brain aneurysms (such as embolic coils, flow diversion devices, intracranial stents, and others), ischemic strokes (like clot retriever devices, suction and aspiration tools, vascular snares, balloon catheters, and more), carotid artery stenosis (including carotid artery stents, embolic protection devices, and balloon catheters), arteriovenous malformations and fistulas (such as liquid embolic agents, occlusion balloon catheters, microcatheters), and other related conditions. Neurovascular devices are essential for accurate diagnosis, effective treatment, and comprehensive management of neurovascular disorders. By enabling timely interventions and enhancing procedural success, these technologies help reduce complications and promote better patient recovery. The market serves patients, healthcare professionals, and medical institutions, driven by continuous advancements in device technology, the rising prevalence of neurovascular disorders, and increasing demand for innovative, minimally invasive, and user-friendly treatment options.
Stakeholders
- Neurovascular devices’ manufacturing companies
- Contract manufacturers
- Distributors, suppliers, and channel partners of neurovascular devices
- Senior Management
- Finance Department
- Procurement Department
- Hospitals & Clinics
- E-commerce and Digital Platforms
- Academic & Research Institutes
- Trade Associations and Industry Bodies
- Regulatory Bodies and Government Agencies
- Business Research and Consulting Service Providers
- Market Research and Consulting Firms
- Venture Capitalists and Investors
Report Objectives
- To define, describe, segment, analyse, and forecast the global neurovascular devices market by disease pathology, end user, and region
- To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To analyze micro markets concerning individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the neurovascular devices market in North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC countries
- To profile the key players in the neurovascular devices market and comprehensively analyze their core competencies
- To track and analyze competitive developments such as agreements, collaborations, and partnerships; expansions; acquisitions; and product launches & approvals in the neurovascular devices market
Get the Full Neurovascular Devices Market Report
Full forecast, segment splits, and company analysis for all Neurovascular Devices Market.
- Canada Neurovascular Devices Market
- US Neurovascular Devices Market
- Germany Neurovascular Devices Market
- France Neurovascular Devices Market
- UK Neurovascular Devices Market
- Italy Neurovascular Devices Market
- Spain Neurovascular Devices Market
- Japan Neurovascular Devices Market
- China Neurovascular Devices Market
- India Neurovascular Devices Market
- South Korea Neurovascular Devices Market
- Brazil Neurovascular Devices Market
- Mexico Neurovascular Devices Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report